Idiotype-specific immunotherapy in multiple myeloma: Suggestions for future directions of research

Haematologica

Volumn 91, Issue 7, 2006, Pages 941-948

  Bogen, Bjarne ^a   Ruffini, Pier Adelchi ^a   Corthay, Alexandre ^a   Fredriksen, Agnete B ^a   Frøyland, Marianne ^a   Lundin, Katrin ^a   Røsjø, Egil ^a   Thompson, Keith ^a   Massaia, Massimo ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Cancer; Idiotype; Immunosurveillance; T cells; Tolerance

Indexed keywords

PARAPROTEIN;

CANCER SURVIVAL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; MULTIPLE MYELOMA; REVIEW;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; MULTIPLE MYELOMA;

EID: 33745802534     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Harousseau JL. Stem cell transplantation in multiple myeloma (0, 1, or 2). Curr Opin Oncol 2005;17:93-8.
2. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999;17:208-15.
3. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005;105:4532-9.
4. Bruno B, Giaccone L, Rotta M, Anderson K, Boccadoro M. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 2005;19:1729-38.
5. Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, et al. New drugs for treatment of multiple myeloma. Lancet Oncol 2004;5:430-42.
6. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003;4:379-98.
7. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
8. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005;54:187-207.
9. Pellat-Deceunynck C, Mellerin MP, Labarriere N, Jego G, Moreau-Aubry A, Harousseau JL, et al. The cancer germline genes MAGE-1, MAGE-3 and FRAME are commonly expressed by human myeloma cells. Eur J Immunol 2000;30:803-9.
10. van Baren N, Brasseur F, Godelaine D, Harnes G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999;94:1156-64.
11. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGE-Cl) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005;106:167-74.
12. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005;105:3939-44.
13. Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, et al. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 1999;93:1287-98.
14. Choi C, Witzens M, Bucur M, Feuerer M, Sommerfeldt N, Trojan A, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005;105:2132-4.
15. Lim SH, Wang Z, Chiriva-Intemati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001;97:1508-10.
16. Lotz C, Mutallib SA, Oehlrich N, Liewer U, Ferreira EA, Moos M, et al. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL. J Immunol 2005;175:1301-9.
17. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-33.
18. +) T lymphocytes. Proc Natl Acad Sci USA 1999;96:2982-7.
19. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002;25:72-81.
20. Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 2004;104:3688-96.
21. Ozaki S, Kosaka M, Wakahara Y, Ozaki Y, Tsuchiya M, Koishihara Y, et al. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 1999;93:3922-30.
22. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997;90:4206-11.
23. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 2002;99:13009-13.
24. Dhodapkar MV, Krasovsky J, Osman K, Geller MD. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003;198:1753-7.
25. Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005;65:2026-34.
26. Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003;102:1435-42.
27. Tonegawa S. Somatic generation of antibody diversity. Nature 1983;302:575-81.
28. Sahota SS, Leo R, Hamblin TJ, Stevenson FK. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood 1997;89:219-26.
29. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 1972;69:1540-4.
30. Cao W, Myers-Powell BA, Braciale TJ. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J Exp Med 1994;179:195-202.
31. Corthay A, Lundin KU, Munthe LA, Froyland M, Gedde-Dahl T, Dembic Z, et al. Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models. Cancer Immunol Immunother 2004;53:759-69.
32. Lauritzsen GF, Bogen B. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells. Cell Immunol 1993;148:177-88.
33. Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 1994;91:5700-4.
34. + T cells confer idiotype-specific tumor resistance in the absence of antibodies. Eur J Immunol 1995;25:3079-86.
35. Dembic Z, Schenck K, Bogen B. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci USA 2000;97:2697-702.
36. Dembic Z, Rottingen JA, Dellacasagrande J, Schenck K, Bogen B. Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level. Blood 2001;97:2808-14.
37. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005;22:371-83.
38. + T cell expansions are found preferentially in patients with a low tumor burden. Eur J Immunol 1997;27:2245-52.
39. Mariani S, Coscia M, Even J, Peola S, Foglietta M, Boccadoro M, et al. Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. Br J Haematol 2001;113:1051-9.
40. Sze DM, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment. Blood 2001;98:2817-27.
41. Sze DM, Brown RD, Yang S, Gibson J, Ho J, Fazekas de St GB, et al. Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leuk Lymphoma 2003;44:1557-68.
42. Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood 2001;98:2992-8.
43. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100:230-7.
44. Fiore F, Nuschak B, Peola S, Mariani S, Muraro M, Foglietta M, et al. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. Eur J Immunol 2005;35:1155-63.
45. Osterborg A, Yi Q, Bergenbrant S, Holm G, Lefvert AK, Mellstedt H. Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. Br J Haematol 1995;89:110-6.
46. Yi Q, Bergenbrant S, Osterborg A, Osby E, Ostman R, Bjorkholm M, et al. T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol 1993;38:529-34.
47. Dianzani U, Pileri A, Boccadoro M, Palumbo A, Pioppo P, Bianchi A, et al. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. Blood 1988;72:1064-8.
48. Fagerberg J, Yi Q, Gigliotti D, Harmenberg U, Ruden U, Persson B, et al. T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer 1999;80:671-80.
49. Hansson L, Rabbani H, Fagerberg J, Osterborg A, Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 2003;101:4930-6.
50. Wen YJ, Ling M, Lim SH. Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma. Br J Haematol 1998;100:464-8.
51. Yi Q, Osterborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995;86:3043-9.
52. Li Y, Bendandi M, Deng Y, Dunbar C, Munshi N, Jagannath S, et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood 2000;96:2828-33.
53. Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001;97:1750-5.
54. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, et al. Idiotype immunization combined with granulocyte- macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specitic T-cell responses. Blood 1998;91:2459-66.
55. Bergenbrant S, Yi Q, Osterborg A, Biorkholm M, Osby E, Mellstedt H, et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 1996;92:840-6.
56. Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999;94:673-83.
57. Cull G, Durrant L, Stainer C, Haynes A, Russell N. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol 1999;107:648-55.
58. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999;83:215-22.
59. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 1999;93:2411-9.
60. Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000;108:805-16.
61. Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998;4:957-62.
62. Yi Q, Desikan R, Barlogie B, Munshi N. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 2002;117:297-305.
63. Coscia M, Mariani S, Battaglio S, Di BC, Piore F, Foglietta M, et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 2004;18:139-45.
64. Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003;101:4607-10.
65. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-7.
66. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26.
67. Bogen B, Malissen B, Haas W. Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 1986;16:1373-8.
68. Bogen B, Lambris JD. Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. EMBO J 1989;8:1947-52.
69. Bogen B, Jorgensen T, Hannestad K. T helper ceU recognition of idiotopes on λ2 light chains of M315 and T952: evidence for dependence on somatic mutations in the third hypervariable region. Eur J Immunol 1985;15:278-81.
70. Bogen B, Snodgrass R, Briand JP, Hannestad K. Synthetic peptides and -chain gene rearrangements reveal a diversified T cell repertoire for a λ light chain third hypervariable region. Eur J Immunol 1986;16:1379-84.
71. Bogen B, Dembic Z, Weiss S. Clonal deletion of specific thymocytes by an immunoglobulin idiotype. EMBO J 1993;12:357-63
72. Eyerman MC, Zhang X, Wysocki LJ. T cell recognition and tolerance of antibody diversity. J Immunol 1996;157:1037-46.
73. Guo W, Smith D, Guth A, Aviszus K, Wysocki LJ. T cell tolerance to germline-encoded antibody sequences in a lupus-prone mouse. J Immunol 2005;175:2184-90.
74. Snyder CM, Aviszus K, Heiser RA, Tonkin DR, Guth AM, Wysocki LJ. Activation and tolerance in CD4(+) T cells reactive to an immunoglobulin variable region. J Exp Med 2004;200:11.
75. Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996;26:2671-9.
76. Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B. Clonal deletion of thymocytes as a tumor escape mechanism. Int J Cancer 1998;78:216-22.
77. Cao W, Myers-Powell BA, Braciale Tf. The weak CD8+ CTL response to an influenza hemagglutinin epitope reflects limited T cell availability. J Immunol 1996;157:505-11.
78. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
79. Mokyr MB, Dray S. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Cancer Res 1983;43:3112-9.
80. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44.
81. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006;107:301-4
82. + regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940-9.
83. Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant 1997;3:157-63.
84. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
85. Singh NJ, Schwartz RH. The strength of persistent antigenic stimulation modulates adaptive tolerance in peripheral CD4+ T cells. J Exp Med 2003;198:1107-17.
86. Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting P38 map kinase signaling restores the function of dendritic cells in multiple myeloma. Blood 2006;107:2432-9.
87. Rapoport AF, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005;11:1230-7.
88. Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 2005;104:1428-33.
89. Bae JE, Yu-Tzu T, Hidesima K, Catley L, Li X, Prabhala RH. Proteasome inhibitor does not affect the function of human immune system: effects on dendritic cells, T lymphocytes and NK cells. Blood 2005;106:[abstract 3930].
90. Bendandi M, Rodriguez-Calvillo M, Inoges S, Lopez-Diaz de CA, Perez-Simon JA, Rodriguez-Caballero A, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma 2006;47:29-37.
91. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 1995;145:211-28.
92. Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996;2:1038-41.
93. Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 2001;97:1370-7.
94. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993;362:755-8.
95. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17:253-8.
96. Huang HI, Wu PY, Teo CY, Chen MN, Chen YC, Silin D, et al. Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand. Int J Cancer 2004;108:696-703.
97. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998;4:1281-6.
98. Hakim I, Levy S, Levy R. A nine-amino acid peptide from IL-1β augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996;157:5503-11.
99. Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005;174:6292-8.
100. Fredriksen AB, Sandlie I, Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther 2006;13:776-85.
101. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 2005;36:315-23.
102. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-20.
103. Kim SB, Baskar S, Kwak LW. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. Leuk Lymphoma 2003;44:1201-8.
104. Geffroy-Luseau A, Moreau-Aubry A, Bataille R, Fellat-Deceunynck C. Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells. Int Immunol 2005;17:1193-200.
105. + T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies. Blood 2003;102:605-12.
106. Armstrong AC, Dermime S, Mulryan K, Stern PL, Bhattacharyya T, Hawkins RE. Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma. J Immunother 2004;27:227-31.
107. Bridges SH. Participation of the humoral immune system in the myeloma-specific transplantation resistance. J Immunol 1978;121:479-83.
108. Bridges SH. Myeloma-specific transplantation resistance: a requirement for complete Freund's adjuvant stimulation of effectors. J Immunol 1978;120:613-8.